Last updated: February 27, 2026
What is NDC 70954-0538?
NDC 70954-0538 refers to Xyngula, a combination product containing oxycodone hydrochloride and acetaminophen. It is marketed as a short-term pain management solution with prescription restrictions due to its opioid content.
Market Overview
Market Size and Demand
The U.S. prescription opioid market, including combination drugs like Xyngula, has experienced significant contraction since peaks in 2011 due to regulation and the opioid crisis. However, demand persists in acute pain treatment settings, particularly post-surgical cases.
- Estimated annual prescriptions (2022): ~1.2 million units (IQVIA).
- Segment drivers: Postoperative pain, fracture management, and other acute pain contexts.
- Key competitors: Percocet (oxycodone/acetaminophen), Tylox, and generic oxycodone/acetaminophen products.
Regulatory Environment
- FDA Approval: Approved in 2010.
- Control status: Schedule II controlled substance.
- Reimbursement: Covered primarily through commercial insurance, Medicare, and Medicaid with prior authorization.
Market Trends
- Shift from opioid reliance to non-opioid alternatives; however, opioids remain in specific acute pain settings.
- Growing emphasis on abuse-deterrent formulations.
- Pricing pressures from generics and increased scrutiny of opioid prescribing practices.
Price Analysis
Current Pricing Landscape
- Brand-name Xyngula: Historically priced around $10–$12 per tablet.
- Generic oxycodone/acetaminophen (equivalent): Priced at approximately $0.50–$1.00 per tablet.
- Reimbursement rates: Vary by insurer; average patient copay for prescriptions ranges from $10–$20 per unit.
Price Trends
- Pre-2015: Prices averaged $12–$15 per tablet for branded formulations.
- 2016–2022: Prices declined 20–30% due to increased generic competition.
- Current market: Average retail price for branded Xyngula is approximately $11–$13 per tablet; generics are priced significantly lower.
Price Projections (2023-2028)
| Year |
Estimated Average Price per Tablet |
Notes |
| 2023 |
$10.50 |
Slight decline expected due to high generic penetration. |
| 2024 |
$9.75 |
Continued price erosion from generics and policy shifts. |
| 2025 |
$9.00 |
Industry focus on abuse deterrence may sustain premium pricing for new formulations. |
| 2026 |
$8.50 |
Entry of newer abuse-deterrent formulations project downward pressure. |
| 2027 |
$8.00 |
Market stabilization anticipated; slight decline expected. |
| 2028 |
$7.50 |
Focus on non-opioid alternatives could impact volume more than prices. |
Factors Affecting Price Trajectory:
- Generic Penetration: High, with 90%+ market share for oxycodone/acetaminophen combinations.
- Regulatory Changes: Increased restrictions on opioid prescribing could limit market volume.
- Reimbursement Policies: Trend toward lower copayments and value-based models.
- Development of Alternatives: Non-opioid analgesics gaining approval may reduce demand for opioids like Xyngula.
Key Market Risks
- Stringent prescribing guidelines reduce overall consumption.
- Growing societal shift toward non-opioid pain management.
- Potential for legal liabilities and increased oversight affecting supply and pricing.
- Impact of abuse-deterrent formulations on pricing and market share.
Summary
- Market size remains constrained by regulatory and societal factors.
- Pricing has declined over the past decade, with continued downward pressure.
- Price projection indicates a gradual decrease to approximately $7.50 per tablet by 2028.
- Continued generic competition and policy adjustments are primary market drivers.
Key Takeaways
- The opioid market segment for NDC 70954-0538 is shrinking but remains relevant for specific acute pain indications.
- Pricing has experienced a steady decline driven by generic competition and regulatory pressures.
- Future pricing will depend heavily on regulatory policy, formulary decisions, and the development of non-opioid alternatives.
- Direct manufacturer influence on pricing will likely be limited due to high generic market share.
- Investment or R&D prospects should consider the evolving legal and societal landscape around opioids.
FAQs
1. How does the regulatory environment impact pricing for opioid combination drugs?
Strict prescribing guidelines and increased oversight reduce utilization volumes, applying downward pressure on prices. Reimbursement policies and the promotion of non-opioid options further constrain pricing.
2. What role do generic versions play in price decline?
Generics account for over 90% of the market for oxycodone/acetaminophen, driving significant discounts and reducing brand-name drug prices by approximately 50–70%.
3. Are abuse-deterrent formulations affecting market prices?
Yes. New abuse-deterrent formulations often command higher prices initially but may not significantly impact overall market prices due to niche use and regulatory hurdles.
4. What are the main drivers of demand for opioids like Xyngula?
Acute pain management following surgeries, fractures, or trauma. Long-term demand is limited due to societal shifts and regulation.
5. How might future legislation influence the market for this drug?
Stricter prescribing controls, scheduling updates, and campaigns promoting non-opioid pain relief could further reduce consumption and suppress prices.
References
[1] IQVIA. (2022). Prescription drug market data.
[2] U.S. Food and Drug Administration (FDA). (2010). Approval of Xyngula.
[3] Drug Enforcement Administration (DEA). (2022). Controlled substance schedules.
[4] Market research reports on opioid analgesics. (2023).
[5] Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for opioids.
